Skip directly to searchSkip directly to the site navigationSkip directly to the page's main content

Health Indicator Report of Prostate Cancer Deaths

Prostate cancer is the second most commonly occurring form of cancer for men, and is the second leading cause of cancer death for men in both Utah and the U.S.

Prostate Cancer Deaths per 100,000 Men by Year, Utah and U.S., 1999-2020

Notes

ICD-10 codes used to define prostate cancer: C61.   [[br]] Age-adjusted to U.S. 2000 standard population.

Data Sources

  • Utah Death Certificate Database, Office of Vital Records and Statistics, Utah Department of Health
  • Population Estimates: National Center for Health Statistics (NCHS) through a collaborative agreement with the U.S. Census Bureau, IBIS Version 2020
  • U.S. Cancer Statistics: WONDER Online Database. United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Accessed at [http://wonder.cdc.gov/cancer.html]
  • National Vital Statistics System, National Center for Health Statistics, U.S. Centers for Disease Control and Prevention

Definition

The rate of death from cancer of the prostate (ICD-10: C61) per 100,000 men.

Numerator

The number of deaths due to prostate cancer for a given year (ICD-10: C61).

Denominator

The male population in Utah or the U.S. for a given year.

Healthy People Objective C-7:

Reduce the prostate cancer death rate
U.S. Target: 21.8 deaths per 100,000 males

Other Objectives

CSTE Chronic Disease Indicators

How Are We Doing?

In 2020, the Utah age-adjusted prostate cancer mortality rate was 21.2 deaths per 100,000 males. Tooele County Local Health District (LHD) had the highest prostate cancer mortality rate at 30.6 per 100,000 and the San Juan LHD had the lowest at 9.5 per 100,000, though caution should be used in interpreting the San Juan LHD rate as it has a high coefficient of variation (see additional data views for additional differences between Utah Small Areas) from 2016-2020. From 2016-2020, men who racially identify as Asian had a significantly lower rate of prostate cancer mortality (6.6 deaths per 100,000 males, though caution should be used in interpreting these rates as these estimates have a high coefficient of variation), while men who racially identify as Pacific Islander had a significantly higher rate of prostate cancer mortality (37.1 per 100,000 males) compared to other races.

How Do We Compare With the U.S.?

The U.S. prostate cancer age-adjusted mortality rate has generally been decreasing over time, from 24.2 deaths per 100,000 males in 2007 to 18.9 deaths per 100,000 males in 2018. The Utah age-adjusted prostate cancer mortality rate trend has been more variable from year-to-year, though rates have generally been similar to the national rate. In 2018, the Utah age-adjusted prostate cancer mortality rate was 22.2 deaths per 100,000 males while the national rate was 18.9 deaths per 100,000 males.

What Is Being Done?

The Utah Comprehensive Cancer Control program (CCC) and its affiliated coalition, the Utah Cancer Action Network (UCAN), work together with state and local partners to reduce the burden of cancer in Utah. Their mission is to lower cancer incidence, morbidity, and mortality in Utah through collaborative efforts directed toward cancer prevention and control. As a result, they support community-based strategies around food security, healthy neighborhoods, access to health care, and financial toxicity in order to prevent cancer; detect cancer early; and improve the lives of cancer survivors, caregivers, and their families.

Evidence-based Practices

Screening recommendations have changed over time. Until recently, many doctors and professional organizations encouraged yearly PSA screening for men beginning at age 50. However, as more has been learned about both the benefits and harms of prostate cancer screening, a number of organizations have begun to caution against routine population screening. Although some organizations continue to recommend PSA screening, there is widespread agreement that any man who is considering getting tested should first be informed in detail about the potential harms and benefits. Since 2018, the U.S. Preventive Services Task Force (USPSTF) recommends that those aged 55-69 with a prostate discuss the potential benefits and potential harms of prostate-specific antigen (PSA)-based screening for prostate cancer before deciding on whether or not to be screened. Healthy diet, exercise, and lifestyle play an important role in cancer prevention.

Available Services

Currently, Medicare provides coverage for an annual PSA test for all Medicare-eligible men age 50 and older. Many private insurers cover regular PSA screening tests as well. Check with your insurance provider and doctor's office to discuss when prostate cancer screening may be right for you.
Page Content Updated On 04/14/2022, Published on 04/27/2022
The information provided above is from the Department of Health's Center for Health Data IBIS-PH web site (http://ibis.health.state.gov). The information published on this website may be reproduced without permission. Please use the following citation: " Retrieved Mon, 26 September 2022 14:08:20 from Department of Health, Center for Health Data, Indicator-Based Information System for Public Health Web site: http://ibis.health.state.gov ".

Content updated: Wed, 27 Apr 2022 15:50:04 MDT